Safety and efficacy of durvalumab with R-CHOP or R
Publication Title
International journal of hematology
Document Type
Article
Publication Date
11-19-2021
Keywords
washington; seattle; swedish cancer; Diffuse large B-cell lymphoma; Durvalumab; High risk; R-CHOP
Abstract
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
COinS
